Philip Morris International to Host Webcast of 2026 Third — Quarter and First Nine — Months Results

For best results when printing this announcement, please click on link below: Philip Morris International to Host Webcast of 2026 Third-Quarter and First Nine-Months Results Regulatory News: Philip Morris International Inc. m. m. ET the same day.

The webcast can be accessed here The webcast will be hosted by Massimo Andolina, Group Chief Financial Officer, and will include discussion of PMI’s financial results and a Q&A session with the investment community. The webcast will be in a listen-only mode. The webcast may also be accessed on mobile devices by downloading PMI’s Investor Relations App at ( ). The webcast recording and the slides and script will be available here ( ).

The recording will be available for one year after the event. Philip Morris International: A Global Smoke-Free Champion Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, nicotine pouch and e-vapor products.

Our smoke-free products are available for sale in over 105 markets, and as of December 31, 2025, PMI estimates they were used by over 43 million legal-age consumers around the world, many of whom have moved away from cigarettes or significantly reduced their consumption. The smoke-free business accounted for approximately 42% of PMI’s second-quarter 2026 total net revenues. Since 2008, PMI has invested over $16 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for legal age adults who would otherwise smoke or use other nicotine-containing consumer products, with the goal of completely ending the sale of cigarettes.

This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. S. Food and Drug Administration has authorized the marketing of Swedish Match’s General snus, ZYN nicotine pouches and versions of PMI’s IQOS devices and consumables — the first-ever such authorizations in their respective categories. Versions of IQOS devices and consumables, General snus and 20 ZYN nicotine pouch variants also obtained the first-ever Modified Risk Tobacco Product authorizations from the FDA in their respective categories.

With a strong foundation and significant expertise in life sciences, PMI has a long-term ambition to expand into wellness areas. , and its subsidiaries. For more information, please visit and ( ). com) Stamford, CT: +1 (203) 905 2410 Lausanne: +41 (0)58 242 4500